Modified Polynucleotides for the production of biologics and proteins associated with human disease

US10772975B2 · kind B2 · utility

Assignee

• ModernaTX, Inc. · US

Inventors

• Stephane Bancel · Cambridge, US
• Tirtha Chakraborty · Medford, US
• Antonin de Fougerolles · Waterloo, BE
• Sayda M. Elbashir · Cambridge, US
• Matthias John · Hallstadt, DE
• Atanu Roy · Stoneham, US
• Susan Whoriskey · Belmont, US
• Kristy M. Wood · Wellesley, US
• Paul Hatala · Boston, US
• Jason P. Schrum · Philadelphia, US
• Kenechi Ejebe · New York, US
• Jeff Lynn Ellsworth · Lexington, US
• Justin Guild · Framingham, US

Key dates

• Filing date: Oct 23, 2017
• Grant date: Sep 15, 2020
• Expiry date: Oct 23, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5′-cap, 5′-UTR, a 3′-UTR, and a poly-A region with at least 100 nucleotides.